NCT04865887View on ClinicalTrials.gov

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 7, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions
Cervical CancerMetastatic Cervical Cancer
Interventions
DRUG

Pembrolizumab

200mg, every 3 weeks, IV infusion

DRUG

Lenvatinib

20 mg (2 capsules x10mg), daily, orally

Trial Locations (4)

20007

RECRUITING

MedStar Georgetown University Hospital, Washington D.C.

20010

WITHDRAWN

Medstar Washington Hospital Center, Washington D.C.

30912

RECRUITING

Georgia Cancer Center at Augusta University, Augusta

07601

RECRUITING

John Theurer Cancer Center at Hackensack UMC, Hackensack

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Georgetown University

OTHER